|
2025 Journal Article Expert Position Statement: Defining the Role of Intestinal Ultrasound in Assessing Constipation and Faecal LoadingMathias, Ryan M., Goodsall, Thomas M., Parker, Claire E., Day, Alice S., An, Yoon K., Baraty, Brandon, Basnayake, Chamara, Begun, Jakob, Boyapati, Ray K., Burgell, Rebecca, Dolinger, Michael T., Maconi, Giovanni, Novak, Kerri L., Sagami, Shintaro, Smith, Rebecca L., Srinivasan, Ashish R., Taylor, Stuart A., Jairath, Vipul, Ma, Christopher and Bryant, Robert V. (2025). Expert Position Statement: Defining the Role of Intestinal Ultrasound in Assessing Constipation and Faecal Loading. Alimentary Pharmacology & Therapeutics. doi: 10.1111/apt.70250 |
|
2025 Journal Article Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s diseaseGilmore, Robert, Murali, Amrutha, Etchegaray, Amirah, Swe, Ei, An, Yoon-Kyo and Begun, Jakob (2025). Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease. Intestinal Research. doi: 10.5217/ir.2024.00174 |
|
2025 Journal Article Su1943: CORRELATION OF BIOCHEMICAL, ENDOSCOPIC AND HISTOLOGIC ENDPOINTS IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS: A POST-HOC ANALYSIS FROM THE VIEWS RANDOMISED CONTROLLED TRIALPudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline L., Redmond, Diane, Chan, Pak Wo, Mourad, Fadi H., Kermeen, Melissa and Leong, Rupert (2025). Su1943: CORRELATION OF BIOCHEMICAL, ENDOSCOPIC AND HISTOLOGIC ENDPOINTS IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS: A POST-HOC ANALYSIS FROM THE VIEWS RANDOMISED CONTROLLED TRIAL. Gastroenterology, 169 (1), S-900. doi: 10.1016/s0016-5085(25)03004-5 |
|
2025 Journal Article Su1899: EXTENSIVE DISEASE CLEARANCE AS A NOVEL COMPOSITE ENDPOINT TO PREDICT LONG-TERM RELAPSE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS: A POST-HOC ANALYSIS FROM THE VIEWS RANDOMISED CONTROLLED TRIALPudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline L., Redmond, Diane, Chan, Pak Wo, Mourad, Fadi H., Kermeen, Melissa and Leong, Rupert (2025). Su1899: EXTENSIVE DISEASE CLEARANCE AS A NOVEL COMPOSITE ENDPOINT TO PREDICT LONG-TERM RELAPSE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS: A POST-HOC ANALYSIS FROM THE VIEWS RANDOMISED CONTROLLED TRIAL. Gastroenterology, 169 (1), S-879. doi: 10.1016/s0016-5085(25)02960-9 |
|
2025 Journal Article Tu1094: PATTERNS AND PREDICTORS OF STEROID USE IN PEOPLE WITH IBD IN ROUTINE CARE ACROSS ANZRivas, Consuelo, Su, Wai Kin, Wilson, William E., Ng, Watson, Ghaly, Simon, Walker, Gareth, Forbes, Angela J., Su, Heidi, Schultz, Michael, Lawrance, Ian C., Dutt, Shoma, Brett, Laurel, Begun, Jakob, Lynch, Kate D., Andrews, Jane M. and Connor, Susan J. (2025). Tu1094: PATTERNS AND PREDICTORS OF STEROID USE IN PEOPLE WITH IBD IN ROUTINE CARE ACROSS ANZ. Gastroenterology, 169 (1), S-1305. doi: 10.1016/s0016-5085(25)03886-7 |
|
2025 Journal Article Colon‐targeted complement C5a<sub>1</sub> receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitisCui, Cedric S., Lerskiatiphanich, Titaya, Li, Xaria X., Giri, Rabina, Liu, Ning, Kumar, Vinod, Whittaker, Andrew K., Han, Felicity Y., Clark, Richard J., Begun, Jakob, Lee, John D. and Woodruff, Trent M. (2025). Colon‐targeted complement C5a1 receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitis. British Journal of Pharmacology, 182 (16), 3852-3869. doi: 10.1111/bph.70056 |
|
2025 Journal Article The durability of anti-TNF therapy for Crohn’s Disease is higher in anti-TNF naïve patients and increases with proactive therapeutic drug monitoringGilmore, Robert, Fernandes, Richard, Schildkraut, Tamar, Joshi, Riddhi, Lin, Lyman, Vorgin, Sara, Etchegaray, Amirah, Shanmuga Anandan, Aathavan, Tambakis, George, Loebenstein, Moshe, An, Yoon-Kyo, Begun, Jakob and Wright, Emily K (2025). The durability of anti-TNF therapy for Crohn’s Disease is higher in anti-TNF naïve patients and increases with proactive therapeutic drug monitoring. Crohn's and Colitis 360, 7 (2) otaf028, 1-9. doi: 10.1093/crocol/otaf028 |
|
2025 Journal Article SCFA biotherapy delays diabetes in humanized gnotobiotic mice by remodeling mucosal homeostasis and metabolomeTillett, Bree J., Dwiyanto, Jacky, Secombe, Kate R., George, Thomas, Zhang, Vivian, Anderson, Dovile, Duggan, Emily, Giri, Rabina, Loo, Dorothy, Stoll, Thomas, Morrison, Mark, Begun, Jakob, Hill, Michelle M., Gurzov, Esteban N., Bell, Kirstine J., Saad, Sonia, Barlow, Christopher K., Creek, Darren J., Chong, Chun Wie, Mariño, Eliana and Hamilton-Williams, Emma E. (2025). SCFA biotherapy delays diabetes in humanized gnotobiotic mice by remodeling mucosal homeostasis and metabolome. Nature Communications, 16 (1) 2893, 1-20. doi: 10.1038/s41467-025-58319-y |
|
2025 Journal Article Cannabidiol targets colorectal cancer cells via cannabinoid receptor 2, independent of common mutationsMoniruzzaman, Md, Wong, Kuan Yau, Janjua, Taskeen Iqbal, Martin, Jennifer H., Begun, Jakob and Popat, Amirali (2025). Cannabidiol targets colorectal cancer cells via cannabinoid receptor 2, independent of common mutations. ACS Pharmacology and Translational Science, 8 (2), 543-556. doi: 10.1021/acsptsci.4c00644 |
|
2025 Journal Article Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studiesRubin, David T., Allegretti, Jessica R, Panés, Julián, Shipitofsky, Nicole, Yarandi, Shadi S, Huang, Kuan-Hsiang Gary, Germinaro, Matthew, Wilson, Rebbecca, Zhang, Hongyan, Johanns, Jewel, Feagan, Brian G, Hisamatsu, Tadakazu, Lichtenstein, Gary R, Bressler, Brian, Peyrin-Biroulet, Laurent, Sands, Bruce E, Dignass, Axel, Abrahamovych, Orest, Abu-Farsakh, Niazy, Afanasieva, Halyna, Akpinar, Hale, Kharrat, Houssam Al, Altintas, Engin, Altwegg, Romain, Andreev, Pavel, Aomatsu, Kazuki, Araki, Hiroshi, Argollo, Marjorie, Ariel, Federico ... Zureikat, Firas (2025). Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. The Lancet, 405 (10472), 33-49. doi: 10.1016/S0140-6736(24)01927-5 |
|
2025 Journal Article Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease CoalitionAkyüz, Filiz, An, Yoon Kyo, Begun, Jakob, Aniwan, Satimai, Bui, Huu Hoang, Chan, Webber, Choi, Chang Hwan, Chopdat, Nazeer, Connor, Susan J, Desai, Devendra, Flanagan, Emma, Kobayashi, Taku, Lai, Allen Yu-Hung, Leong, Rupert W, Leow, Alex Hwong-Ruey, Leung, Wai Keung, Limsrivilai, Julajak, Muzellina, Virly Nanda, Peddi, Kiran, Ran, Zhihua, Wei, Shu Chen, Sollano, Jose, Teo, Michelle Mui Hian, Wu, Kaichun, Ye, Byong Duk and Ooi, Choon Jin (2025). Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition. Intestinal Research, 23 (1), 37-55. doi: 10.5217/ir.2024.00089 |
|
2025 Conference Publication Janus Kinase Inhibitors for the Management of Acute Severe Ulcerative Colitis: A Multicentre StudyGilmore, R., Fernandes, R., Chin, S., Con, D., De Cruz, P., Demase, K., Sparrow, M., Thin, L., Baker, J., Venugopal, K., Lucas, S., Garg, M., Loebenstein, M., Nguyen, A., Moore, G., Tandon, B., Bryant, R., MacFarlane, K., Lynch, K., Abdul, S., Subhaharan, D., Mohsen, W., Haig, A., Day, M., White, L., Begun, J. and An, Y. K. (2025). Janus Kinase Inhibitors for the Management of Acute Severe Ulcerative Colitis: A Multicentre Study. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.1203 |
|
2025 Conference Publication Handheld ultrasound devices are an accurate alternative to cart-based ultrasound for IBD disease activity assessmentFernandes, R., Swe, E., Khaing, M. M., Gilmore, R., Khoo, E., An, Y. K. and Begun, J. (2025). Handheld ultrasound devices are an accurate alternative to cart-based ultrasound for IBD disease activity assessment. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.1349 |
|
2025 Conference Publication P0112 Cannabidiol (CBD) targeting of colorectal cancer cells is mutation-independent and via CB2 receptorMoniruzzaman, M., Janjua, T., Begun, J. and Popat, A. (2025). P0112 Cannabidiol (CBD) targeting of colorectal cancer cells is mutation-independent and via CB2 receptor. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.0286 |
|
2025 Conference Publication Correlation of biochemical, endoscopic and histologic endpoints in vedolizumab-treated patients with ulcerative colitis: a post-hoc analysis from the VIEWS randomised controlled trialPudipeddi, A., Dhanji, P., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y. K., Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D., Chan, W., Mourad, F., Kermeen, M. and Leong, R. (2025). Correlation of biochemical, endoscopic and histologic endpoints in vedolizumab-treated patients with ulcerative colitis: a post-hoc analysis from the VIEWS randomised controlled trial. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.0431 |
|
2025 Journal Article Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis: a case reportHuynh, David, Khaing, Myat Myat, Fernandes, Richard Gareth, Malloy, Reuben, Lin, Lei, Gilmore, Robert, Walker, Nicole, Khoo, Emi and Begun, Jakob (2025). Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis: a case report. Case Reports in Gastroenterology, 19 (1), 1-6. doi: 10.1159/000542711 |
|
2025 Journal Article Epidemiology and Treatment Patterns of Fistulizing Crohn's Disease in a Large, Real-World Australasian CohortMcNamara, Jack, Wilson, William, Pipicella, Joseph L., Ghaly, Simon, Begun, Jakob, Lawrance, Ian C., Gearry, Richard, Andrews, Jane M. and Connor, Susan J. (2025). Epidemiology and Treatment Patterns of Fistulizing Crohn's Disease in a Large, Real-World Australasian Cohort. Gastro Hep Advances, 4 (4) 100594, 100594. doi: 10.1016/j.gastha.2024.100594 |
|
2024 Journal Article Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort studyGilmore, Robert, Fernandes, Richard, Hartley, Imogen, Arzivian, Arteen, Leong, Rupert, Andrew, Bridgette, Vasudevan, Abhinav, Greeve, Tessa, Moore, Gregory Thomas, Kim, Steven, Lightowler, Daniel, Singh, Abhey, Mahy, Gillian, Mithanthaya, Aditya, Venugopaul, Kannan, Han, Sangwoo, Bryant, Robert, West, Jack, Segal, Jonathan, Christensen, Britt, Corte, Crispin, Ding, Nik, An, Yoon-Kyo and Begun, Jakob (2024). Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study. Intestinal Research. doi: 10.5217/ir.2024.00127 |
|
2024 Journal Article Does improving depression symptoms in young adults with inflammatory bowel disease alter their microbiome?Davies, Julie M., Teh, Jing Jie, Ewais, Tatjana and Begun, Jakob (2024). Does improving depression symptoms in young adults with inflammatory bowel disease alter their microbiome?. Inflammatory Bowel Diseases, 30 (12), 2428-2439. doi: 10.1093/ibd/izae121 |
|
2024 Conference Publication Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated AnemiaBisht, Kavita, An, Yoon-Kyo, Shatunova, Svetlana, Wang, Ran, Barbier, Valerie, Giri, Rabina, Amiss, Anna, Tang, Yifu, Alexander, Kylie, Millard, Susan, Winkler, Ingrid G., Pettit, Allison, Begun, Jakob and Levesque, Jean-Pierre (2024). Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated Anemia. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-193349 |
